| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/IMJ.12363 |
| P698 | PubMed publication ID | 24621284 |
| P2093 | author name string | J Moore | |
| J Joseph | |||
| F Grimpen | |||
| P Pavli | |||
| K Subramaniam | |||
| A C Clarke | |||
| M Buckland | |||
| D Yeung | |||
| K Fay | |||
| J Elijah | |||
| D Talaulikar | |||
| P2860 | cites work | HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. | Q34561113 |
| Post-transplant hepatosplenic T-cell lymphoma successfully treated with HyperCVAD regimen. | Q36944851 | ||
| A Systematic Review of Factors That Contribute to Hepatosplenic T-Cell Lymphoma in Patients With Inflammatory Bowel Disease | Q37796190 | ||
| Hepatosplenic T-cell lymphoma in patients receiving TNF-α inhibitor therapy: expanding the groups at risk | Q37937410 | ||
| T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study | Q38049119 | ||
| Hepatosplenic and other gammadelta T-cell lymphomas. | Q50694483 | ||
| Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients | Q33349390 | ||
| Hepatosplenic T cell lymphoma. A review on 45 cases since the first report describing the disease as a distinct lymphoma entity in 1990. | Q33949912 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hepatosplenic T-cell lymphoma | Q5731794 |
| P304 | page(s) | 287-290 | |
| P577 | publication date | 2014-03-01 | |
| P1433 | published in | Internal Medicine Journal | Q15749165 |
| P1476 | title | Hepatosplenic T-cell lymphoma, immunosuppressive agents and biologicals: what are the risks? | |
| P478 | volume | 44 |
| Q38253832 | Does a personal or family history of malignancy preclude the use of immunomodulators and biologics in IBD. |
| Q88687934 | Hepatosplenic T cell lymphoma: a unifying entity in a patient with hemolytic anemia, massive splenomegaly, and liver dysfunction |
| Q92060101 | Hepatosplenic T-Cell Lymphoma: A Rare Complication of Monotherapy with Thiopurines in Crohn's Disease |
| Q39050073 | Hepatosplenic T-cell lymphoma arising in patients with immunodysregulatory disorders: a study of 7 patients who did not receive tumor necrosis factor-α inhibitor therapy and literature review |
| Q38618903 | Methotrexate for the Management of Crohn's Disease in Children |
| Q93139615 | Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders with a T- or NK-cell phenotype |
| Q42463320 | Resected Hepatocellular Carcinoma in a Patient with Crohn's Disease on Azathioprine |
| Q37009469 | Use of case reports and the Adverse Event Reporting System in systematic reviews: overcoming barriers to assess the link between Crohn's disease medications and hepatosplenic T-cell lymphoma |
| Q94326524 | Withdrawal of drug therapy for patients with quiescent Crohn's disease |
| Q57689307 | Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn's disease |
Search more.